The news is directly related to Kezar Life Sciences and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook for the company's stock in the short term. However, the impact on the stock price is uncertain as the rating remains positive.